Beractant

Beractant
Clinical data
Trade names Survanta, Alveofact
Routes of
administration		 Endotracheal
ATC code
  • none
Legal status
Legal status
  • UK: POM (Prescription only)
Identifiers
CAS Number
ChemSpider
  • none
UNII
ChEMBL
 NYesY (what is this?)  (verify)

Beractant, also known by the trade name of Survanta, is a modified bovine pulmonary surfactant containing bovine lung extract (phospholipids, neutral lipids, fatty acids, and bovine surfactant proteins), to which synthetic DPPC, tripalmitin and palmitic acid are added. The composition provides 25 mg/mL phospholipids, 0.5 to 1.75 mg/mL triglycerides, 1.4 to 3.5 mg/mL free fatty acids, and <1.0 mg/mL total surfactant proteins.[1] As an intratracheal suspension, it can be used for the prevention and treatment of neonatal respiratory distress syndrome.[2]

References

  1. ↑ Moya, F. R.; Gadzinowski, J.; Bancalari, E.; Salinas, V.; Kopelman, B.; Bancalari, A.; Kornacka, M. K.; Merritt, T. A.; Segal, R.; Schaber, C. J.; Tsai, H.; Massaro, J.; d'Agostino, R. (1 April 2005). "A Multicenter, Randomized, Masked, Comparison Trial of Lucinactant, Colfosceril Palmitate, and Beractant for the Prevention of Respiratory Distress Syndrome Among Very Preterm Infants". PEDIATRICS. 115 (4): 1018–1029. doi:10.1542/peds.2004-2183.
  2. ↑ Lotze, Andrea; Mitchell, Brian R.; Bulas, Dorothy I.; Zola, Elizabeth M.; Shalwitz, Robert A.; Gunkel, J.Harry (January 1998). "Multicenter study of surfactant (beractant) use in the treatment of term infants with severe respiratory failure". The Journal of Pediatrics. 132 (1): 40–47. doi:10.1016/S0022-3476(98)70482-2.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.